Ovarian Cancer Caregivers Have Unique Needs

Leaning on spiritual belief may strengthen patients' life purposes, but for many, it's common to temporarily loosen their grip on faith after a cancer diagnosis.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.